Literature DB >> 1979457

Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines.

T Efferth1, H Löhrke, M Volm.   

Abstract

The natural resistance to doxorubicin of 15 human renal carcinoma cell lines was analyzed and compared to proliferative activity and expression of P-glycoprotein. We found a significant negative correlation between proliferative activity and natural resistance to doxorubicin, as well as between proliferative activity and the expression of P-glycoprotein. A positive correlation between resistance and expression of P-glycoprotein was found.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1979457     DOI： 10.1007/bf00300777

Source DB:  PubMed          Journal:  Urol Res        ISSN： 0300-5623


  22 in total

1.  Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors.

Authors:  T Efferth; H Löhrke; M Volm
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

2.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

Authors:  I Sugawara; I Kataoka; Y Morishita; H Hamada; T Tsuruo; S Itoyama; S Mori
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

3.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

Review 4.  Multidrug-resistance phenotype in Chinese hamster ovary cells.

Authors:  V Ling; N Kartner; T Sudo; L Siminovitch; J R Riordan
Journal:  Cancer Treat Rep       Date:  1983-10

5.  Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems.

Authors:  G S Wood; R Warnke
Journal:  J Histochem Cytochem       Date:  1981-10       Impact factor: 2.479

6.  Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy.

Authors:  M Volm; K Wayss; M Kaufmann; J Mattern
Journal:  Eur J Cancer       Date:  1979-07       Impact factor: 9.162

7.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

8.  Rapid detection assays for multidrug resistance.

Authors:  T Efferth; M Volm
Journal:  Arzneimittelforschung       Date:  1988-12

9.  Induced multidrug-resistance in murine sarcoma 180 cells grown in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins.

Authors:  M Volm; M Bak; T Efferth; J Mattern
Journal:  Anticancer Res       Date:  1988 Nov-Dec       Impact factor: 2.480

10.  Detection of drug resistance and P-glycoprotein in human renal cell carcinomas.

Authors:  M Bak; T Efferth; G Mickisch; J Mattern; M Volm
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096
View more
  3 in total

1.  Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays.

Authors:  N W Lutz; S E Franks; M H Frank; S Pomer; W E Hull
Journal:  MAGMA       Date:  2005-06-23       Impact factor: 2.310

Review 2.  Antibody-directed therapy of multidrug-resistant tumor cells.

Authors:  T Efferth; M Volm
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

3.  Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.

Authors:  Bo Gao; Amanda Russell; Jonathan Beesley; Xiao Qing Chen; Sue Healey; Michelle Henderson; Mark Wong; Catherine Emmanuel; Laura Galletta; Sharon E Johnatty; David Bowtell; Michelle Haber; Murray Norris; Paul Harnett; Georgia Chenevix-Trench; Rosemary L Balleine; Anna deFazio
Journal:  Sci Rep       Date:  2014-05-09       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.